Skip to main content
NEXALIS THERAPEUTICS LTD logo

NEXALIS THERAPEUTICS LTD — Investor Relations & Filings

Ticker · NX1 ISIN · AU0000456733 ASX Professional, scientific and technical activities
Open in API
Filings indexed 509 across all filing types
Latest filing 2025-03-13 Investor Presentation
Country AU Australia
Listing ASX NX1

About NEXALIS THERAPEUTICS LTD

https://nexalistherapeutics.com/

Nexalis Therapeutics Ltd focuses on the discovery and development of innovative small molecule therapies for the treatment of chronic inflammatory and autoimmune diseases. The company utilizes a proprietary drug discovery platform to target specific biological pathways, including the NLRP3 inflammasome, which is implicated in the progression of various systemic and neurodegenerative conditions. By developing highly selective and potent modulators, the organization aims to address significant unmet medical needs in patient populations suffering from debilitating inflammatory disorders. Research and development efforts are centered on translating complex biological insights into clinical-stage therapeutic candidates designed to improve patient outcomes and quality of life through precision targeting of immune system dysregulation.

Recent filings

Filing Released Lang Actions
Shareholder Town Hall - Webinar Slides 19 pages 2.1MB
Investor Presentation Classification · 95% confidence The document is an ASX announcement dated 14 March 2025, containing slides from a shareholder town hall webinar held on 13 March 2025. It includes detailed presentation content about the company's clinical development programs, funding, market context, and future plans. The document is a presentation of information to shareholders and potential investors, focusing on company strategy, clinical progress, and market opportunity. It is not a formal financial report, audit, earnings release, or regulatory filing. The content matches the description of an Investor Presentation (IP), which is a detailed presentation for investors focusing on financials, strategy, and market position. The document length is substantial (over 14,000 characters), and it contains substantive content rather than just an announcement or link to a report. Therefore, the appropriate classification is Investor Presentation (IP).
2025-03-13 English
Study Order Executed for Phase 2 BTcP Trial 2 pages 270.9KB
Capital/Financing Update Classification · 95% confidence The document is a company announcement about the execution of a Study Order for a Phase 2 clinical trial of a drug candidate (IRX-211) for Breakthrough Cancer Pain. It details the study design, patient population, funding, and next steps. There are no financial statements, earnings data, or regulatory filings such as annual or quarterly reports. The content focuses on clinical trial progress and funding arrangements, which is typical of a Capital/Financing Update. The document is about the company's financing facility enabling the trial and the contract with the CRO, not a full financial report or earnings release. Therefore, the best fitting category is Capital/Financing Update (CAP). The document length is about 5,067 characters, which is consistent with an announcement rather than a full report.
2025-03-12 English
Town Hall Webinar - 4pm AEDT on 13 Mar 2025 2 pages 172.2KB
Regulatory Filings Classification · 90% confidence The document is an ASX announcement dated 6 March 2025 inviting shareholders and potential investors to a Shareholder Town Hall Webinar scheduled for 13 March 2025. It includes details about the webinar, speakers, and how to register, but does not contain any financial data, results, or detailed reports. It mentions that presentation slides will be lodged on the ASX prior to the webinar, indicating this document is an announcement rather than the presentation or report itself. The document length is short (2358 characters), and it serves as an invitation and update notice rather than a financial or regulatory report. Therefore, it fits best under Investor Presentation (IP) as it is a detailed presentation for investors focusing on company updates and strategy, albeit in announcement form. However, since the actual presentation slides are not included and this is an announcement of the webinar, the best classification is Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories more specifically.
2025-03-05 English
General Meeting Slides 4 pages 307.7KB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a record of a General Meeting held on 6 March 2025, including agenda items, voting on a resolution, and poll results. It details shareholder voting outcomes and procedural aspects of the meeting. There is no detailed financial data, management discussion, or report content. The document is not an Annual Report, Interim Report, or Earnings Release. It is not a proxy solicitation or remuneration report. The focus is on the voting results and meeting proceedings, which aligns with Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and it contains voting results, confirming it is a voting results announcement rather than a full report or presentation.
2025-03-05 English
Results of General Meeting 3 pages 208.1KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an ASX announcement dated 6 March 2025 reporting the results of a General Meeting of shareholders. It includes details of the resolution voted on, proxy votes, poll results, and the outcome of the resolution. The document also references compliance with section 251AA of the Corporations Act 2001, which pertains to disclosure of voting results. There is no financial data or detailed report content, only the official voting results and related information. The document is relatively short (4205 characters) and serves as an official announcement of voting results rather than the meeting materials or full reports. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-03-05 English
Notification of cessation of securities - IRX 4 pages 14.8KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and details the cessation (expiry) of certain securities (options) for Inhalerx Limited. It includes specific information about the securities that have ceased, the reason for cessation, and the updated issued capital following these changes. The document is a formal announcement related to changes in the company's capital structure, specifically the cessation of securities. It is not a financial report, earnings release, or management discussion. It fits the category of Share Issue/Capital Change announcements, which cover new share issues, stock splits, or other capital changes such as cessation of securities.
2025-03-02 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.